Publicis Health announces today the promotions of Andrew Spurgeon to chief creative officer Europe and Victoria Wright to group managing director.
In his new role, Andrew will have overall responsibility for the standard of creative output from all Publicis Health agencies in Europe, ensuring that the passion and expertise of all of the creative talent is united to deliver best-in-category work for clients. He will report to Philip Chin, president Europe, Publicis Health and to Kathy Delaney, global chief creative officer, Publicis Health.
“I am delighted that we are continuing to provide opportunities for our talent to grow and flourish,” said Philip Chin. “Andrew is an exceptional and hugely respected creative leader. His leadership over the past decade has helped establish Langland as a world-class health and wellness creative powerhouse - winning Cannes Lions Health, Agency of the Year twice, and five times Global Agency of the Year at the New York Festivals Global Awards. His promotion to chief creative officer Europe will undoubtedly result in better creative work across the region, which is great for our agencies and more importantly our clients.”
Additionally, Victoria Wright is promoted to group managing director, adding Langland UK to the portfolio of Publicis Health agencies under her direction in the UK. This move follows the departure of Alison Ferrucci, general manager at Langland UK, who was at the agency for eighteen years. Victoria will continue to report to Philip Chin.
“Victoria is a great business leader with an enviable track record,” comments Philip. “Under her direction, Publicis LifeBrands, Publicis Resolute and Real Science Communications have achieved record-breaking growth over recent years. In her new role as group managing director, Victoria will also take on responsibility for leading Langland in the UK. She is perfectly placed to accelerate the integration of medical education and public relations into our Clinical Trial Experience capability, so that we continue to provide clients with a market-leading and highly differentiated solution to the challenge of recruiting and retaining patients into clinical trials.”